PharMerica CORP
Form 8-K
August 02, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION 

Washington, DC 20549

## FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2012

## PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

# Edgar Filing: PharMerica CORP - Form 8-K 

## Louisville, Kentucky 40299

## (Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (502) 627-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
.. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The employment of William Monast, the Executive Vice President of Sales and Client Management of PharMerica Corporation terminated on August 1, 2012.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PHARMERICA CORPORATION

Date: August 2, 2012
By:/s/ Thomas A. Caneris
Thomas A. Caneris
Senior Vice President and General Counsel

